Floatz logo

Pyrotinib

Richter Transformation

German CLL Study GroupSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Richter Transformation cohort.

Asset / SponsorPhaseRating
Tislelizumab
German CLL Study Group
Phase 2CCC
Zamtocabtagene Autoleucel
Miltenyi Biomedicine GmbH
Phase 2CCC
Sonrotoclax
German CLL Study Group
Phase 2CCC
rc48-adc
German CLL Study Group
Phase 2CCC
Bgb-21447
BeOne Medicines
Phase 1CC
cd19.20.22 car t cells
University of Maryland, Baltimore
Phase 1CC
lp-118
Newave Pharmaceutical Inc
Phase 1CC
1H-Isoindol-1-one, 2,3-dihydro-2-[3-[cis-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[(3S)-3-methyl-1-piperidinyl]methyl]-4-(trifluoromethyl)-
Nurix Therapeutics, Inc.
Phase 1CC

Same molecule, other indications

Pyrotinib is also rated in:

Non Small Cell Lung CancerDormant
BB
Indicative ·
70 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
Small Cell Lung CancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →